<DOC>
	<DOCNO>NCT00754702</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy metronomic oral vinorelbine take three time week plus daily lapatinib without break , salvage treatment patient metastatic breast cancer .</brief_summary>
	<brief_title>Vinorelbine Metronomic Plus Lapatinib Overexpressing HER-2 Metastatic Breast Cancer</brief_title>
	<detailed_description>Continuous administration oral vinorelbine , give three time week ( metronomic ) feasible exceptionally well tolerated dos 50 mg . Early result show activity refractory tumor provide evidence towards clinical proof efficacy metronomic chemotherapy . Recently , lapatinib plus capecitabine proven superior capecitabine alone woman HER2-positive advance breast cancer progress treatment regimen include anthracycline , taxane , trastuzumab .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Histologically cytologically confirm metastatic breast adenocarcinoma Age 1875 year HER2 status positive accord local institution report grade 3+ stain intensity ( scale 0 3 ) mean immunohistochemical analysis grade 2+ stain intensity mean immunohistochemical analysis gene amplification fluorescence situ hybridization Previous therapy include , regimens contain anthracycline taxane Previous treatment trastuzumab , alone combination chemotherapy locally advance metastatic disease , require Measurable disease define presence least one measurable lesion ( except bone metastasis , ascites pleural effusion ) Performance status ( WHO ) 02 Adequate liver ( serum bilirubin &lt; 1.5 time upper normal limit ; AST ALT &lt; 2.5 time upper normal limit absence demonstrable liver metastasis , &lt; 5 time upper normal limit presence liver metastasis ) ; adequate renal function ( serum creatinine &lt; 1.5 time upper normal limit ) ; bone marrow ( neutrophils ≥ 1.5x 109 /L , platelet ≥ 100x 109 /L ) function No radiation measurable disease ( except brain metastasis ) No progressive brain metastasis accord clinical radiological criterion No brain metastases without prior radiation therapy Written inform consent Patient unable take oral medication Active infection History significant cardiac disease ( unstable angina , congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) Other invasive malignancy except nonmelanoma skin cancer Psychiatric illness social situation would preclude study compliance Pregnant lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Vinorelbine metronomic-lapatinib</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Targeted therapy</keyword>
</DOC>